Allogene Therapeutics (ALLO) Receivables - Net (2020)

Allogene Therapeutics' (ALLO) quarterly Receivables - Net came in at $3.1 million in Q3 2020, up 287.5% quarter-over-quarter from $800000.0 in Q2 2020.

Allogene Therapeutics (ALLO) Receivables - Net (2020) Analysis & Trends

Allogene Therapeutics has disclosed Receivables - Net across 1 years of filings, most recently posting $3.1 million for Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Allogene Therapeutics 482.98 Mn 482.98 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2020 3.10 Mn
Sep 30, 2020 3.10 Mn
Jun 30, 2020 800,000.00
Jun 30, 2020 800,000.00
Mar 31, 2020 200,000.00
Mar 31, 2020 200,000.00